MOLECULAR DIAGNOSTIC MULTIPLEXED POINT-OF-CARE TESTING
Sample to answer analysis in less than 30 minutes
To overcome these limitations, British medical device developer QuantuMDx (QMDx) and SCIENION have partnered to take QMDx’s highly multiplexed nanowire array to market. This biosensor is a component of QMDx’s flagship product Q-POC™, a handheld molecular diagnostic device that will provide results in 30 minutes for a few pounds at the patient’s side.
Q-POC™ differs from most conventional point-of-care diagnostic tools in that it analyses the DNA of pathogens rather than the proteins within the sample. The device depends on microfluidic technology, which essentially allows fluids to pass through different microscopic channels of different diameters. The device has a built-in cell phone technology, enabling the test results to be geo-stamped and shared in real time, potentially opening the door to continuous monitoring of disease and antimicrobial resistance.
Dr Jennifer Hannant, Head of Chemistry at QuantuMDx.
The SX: Compact Solution for High Throughput
The companies’ longstanding relationship was cemented with QMDx’s purchase of SCIENION’s sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterisation from R&D to mass manufacturing.